SARS-CoV-2 (COVID-19) Spike RBD Neutralizing Antibody [C-A11]

ProSci
Product Code: PSI-20-186
Product Group: Primary Antibodies
Supplier: ProSci
CodeSizePrice
PSI-20-186-200ul200ul£801.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Rabbit
Antibody Isotype: IgG1k
Antibody Clonality: Monoclonal
Antibody Clone: C-A11
Regulatory Status: RUO
Target Species: Virus
Applications:
  • Flow Cytometry
  • Neutralisation
Shipping:
blue ice or RT
Storage:
SARS-CoV-2 (COVID-19) Spike RBD Neutralizing Antibody [C-A11] can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Images

1 / 4
Flow cytometry neutralizing assay: C-A11 displayed dose dependent blocking of spike proteins (wild type and UK variant) to ACE2 expressing cells.
2 / 4
3 / 4
Flow cytomery neutralizing assay of C-A11 (plotted graphs): ACE2 transfected cells were incubated with biotinylated spike protein (0.5 ug/mL) in the presence or absence of antibody. Binding of spike protein was detected with DyLight488 conjugated StreptAvidin. C-A11 efficiently blocked the binding of wild type and UK variant (B.1.1.7) to ACE2 expressing HEK293 cells.
4 / 4
Binding of C-A11 to SARS-CoV-2 variants (UK and South Africa): C-A11 shows good cross reactivity to both variants B.1.1.7 (UK) and B.1.351 (S. Africa).

Flow cytometry neutralizing assay: C-A11 displayed dose dependent blocking of spike proteins (wild type and UK variant) to ACE2 expressing cells.
Flow cytomery neutralizing assay of C-A11 (plotted graphs): ACE2 transfected cells were incubated with biotinylated spike protein (0.5 ug/mL) in the presence or absence of antibody. Binding of spike protein was detected with DyLight488 conjugated StreptAvidin. C-A11 efficiently blocked the binding of wild type and UK variant (B.1.1.7) to ACE2 expressing HEK293 cells.
Binding of C-A11 to SARS-CoV-2 variants (UK and South Africa): C-A11 shows good cross reactivity to both variants B.1.1.7 (UK) and B.1.351 (S. Africa).

Further Information

Additional Names:
Spike protein S1, Spike protein S2, RBD domain, Binding to ACE-2 receptor, SARS-CoV-2 variants, U.K variant B.1.1.7, South Africa variant B.1.351
Application Note:
Functional Assay: This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2. Can be paired with other antibody for detection in sandwich ELISA format.
Background:
This antibody recognizes the SARS-CoV-2 spike protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2; DPP4, dipeptidyl peptidase-4; APN, aminopeptidase N; CEACAM, carcinoembryonic antigen-related cell adhesion molecule 1; Sia, sialic acid; O-ac Sia, and O-acetylated sialic acid. The spike protein is essential for both host specificity and viral infectivity. The term ?peplomer? is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. It?s been reported that SARS-CoV-2 (COVID-19 coronavirus, 2019-nCoV) can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. The main functions for the spike protein are summarized as: mediates receptor binding and membrane fusion, defines the range of the hosts and specificity of the virus; main component to bind with the neutralizing antibody; key target for vaccine design; and can be transmitted between different hosts through gene recombination or mutation of the receptor binding domain (RBD), leading to a higher mortality rate.
Buffer:
1X PBS
Concentration:
batch dependent
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
U.K coronavirus variant B.1.1.7, South Africa variant B.1.351
Immunogen:
recombinant protein (RBD)
NCBI Gene ID #:
43740568
NCBI Official Name:
surface glycoprotein
NCBI Official Symbol:
S
NCBI Organism:
SARS-CoV-2
Physical State:
Liquid
Protein Accession #:
P0DTC2
Purification:
Protein A
Research Area:
Infectious Disease,COVID-19
Swissprot #:
P0DTC2
User NOte:
Optimal dilutions for each application to be determined by the researcher.